CoChat

Safety and efficacy of insulin degludec/liraglutide (ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial

Open access
Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J., the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators · 2017 · Diabetic Medicine
Cited by 109

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aim: To investigate the safety and efficacy of insulin degludec/liraglutide (ID egLira), a novel combination product, as add‐on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy. Methods: In this 26‐week, double‐blind trial, adults with Type 2 diabetes [HbA 1c 53–75 mmol/mol (7.0–9.0%)] were randomized to ID egLira (n = 289) or placebo (n = 146) as add‐on to pre‐trial sulphonylurea ± metformin, titrating to a fasting glycaemic target of 4.0–6.0 mmol/l. Treatment initiation was at 10 dose steps, and maximum dose was 50 dose steps (50 units insulin degludec/1.8 mg liraglutide). Results: The mean HbA 1c decreased from 63 mmol/mol (7.9%) to 46 mmol/mol (6.4%) with ID egLira and to 57 mmol/mol (7.4%) with placebo [estimated treatment difference –11 mmol/mol (95% CI –13; –10) or –1.02% (95% CI –1.18; –0.87); P < 0.001]. The HbA 1c target of 53 mmol/mol (<7%) was achieved by 79.2% of participants in the ID egLira group vs 28.8% in the placebo group [estimated odds ratio 11.95 (95% CI 7.22; 19.77); P < 0.001]. Mean weight change was +0.5 kg with ID egLira vs –1.0 kg with placebo [estimated treatment difference 1.48 kg (95% CI 0.90; 2.06); P < 0.001]. Confirmed hypoglycaemia occurred in 41.7 and 17.1% of ID egLira‐ and placebo‐treated participants, respectively, with rates of 3.5 vs 1.4 events/patient‐years of exposure [estimated rate ratio 3.74 (95% CI 2.28; 6.13); P < 0.001]. ID egLira was generally well tolerated. The rates of serious adverse events were 20.3 and 8.0 per 100 patient‐years of exposure with ID egLira and placebo, respectively, without obvious patterns in the type of events. Conclusions: ID egLira can be used in people uncontrolled with sulphonylurea ± metformin to improve efficacy with a safety profile in line with previous DUAL trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.13256

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 109

Metadata

Authors
Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J., & the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators
Venue
Diabetic Medicine
Publisher
Wiley
Published
2016-10-07
Volume
34
Issue
2
Pages
189-196
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2516820342
Cited by
109
References
9
FWCI
14.43
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of insulin degludec/liraglutide (ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial. https://app.cochat.ai/papers/10.1111/dme.13256
The paper
Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J., & the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators. (2017). Safety and efficacy of insulin degludec/liraglutide (ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial. Diabetic Medicine. https://doi.org/10.1111/dme.13256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.